DeutschNewstral
Article
jdsupra.com on 2017-06-30 02:55
Does Amgen Have Viable State Law Claims Against Sandoz Arising From The Zarxio Biosimilar Patent Dispute?
Related news
- AbbVie and Sandoz Settle Adalimumab Biosimilar Patent Disputesjdsupra.com
- Amgen Files New Patent Infringement Suit Over Neupogen Biosimilarjdsupra.com
- Amgen v. Sandoz Biosimilar Litigation Update: Sandoz Follows the Patent Dance With Neulastajdsupra.com
- Sandoz Uses Patent Dance to Limit Humira® Biosimilar Lawsuit to Two Patents For Nowjdsupra.com
- Amgen Sues Pfizer and Hospira for Patent Infringement related to Hospira’s Filgrastim Biosimilarjdsupra.com
- Supreme Court Defers Certiorari Decision In Amgen Sandoz Biosimilar Patent Dance Disputejdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com
- Sandoz Launches Adalimumab Biosimilar in Spainjdsupra.com
- Sandoz Inc. v. Amgen Inc. (2017)jdsupra.com
- Sandoz v. Amgen Supreme Court Decisionjdsupra.com
- Amgen Sues Pfizer Over Proposed Neulasta Biosimilarjdsupra.com
- Sandoz Files Responsive Brief in Amgen v. Sandoz Appealjdsupra.com
- Sandoz v. Amgen Supreme Court Oral Argumentjdsupra.com
- Amgen and Sandoz Launch Biosimilars in Europejdsupra.com
- Amgen v. Sandoz -- Federal Circuit Oral Argumentjdsupra.com
- Biosimilar-Related Patent Litigation Updatesjdsupra.com
- Amgen Sues Sandoz Over Biosimilar Version of NEULASTA® (pegfilgrastim)jdsupra.com
- Updates on Sandoz’s Pegfilgrastim Biosimilar / Amgen v. Sandozjdsupra.com
- Amgen, Sandoz, Samsung, and Mylan Launch Biosimilars in Europe (UPDATED)jdsupra.com
- Amgen v. Sandoz BPCIA Dispute Heads to the Federal Circuitjdsupra.com